Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline

Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference

Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished